Bispecific antibodies are capable of bridging two different molecules. In order to fit the desired target-product profile in therapeutic and diagnostic applications, BsAb are usually adjusted in size, valency, flexibility, half-life and biodistribution. BsAbs of different formats have diverse potential action mechanisms. Up to date, at least 30 different BsAbs and related molecules are in clinical development currently, two of which have been approved to be put onto market, catumaxomab (REMOVAB®) and blinatumomab (BLINCYTO®), which also suggests BsAbs can be developed as promising therapeutic agents.

Bispecific antibodies have a wide application range, and we are very proud of offering the custom BsAb services according to your different specific requirements. Our BsAbs application domains mainly include but are not limited to: